SCOPUS
Immuno-Oncology and Technology
Elsevier, United States
Immuno-Oncology and Technology은(는) Elsevier(United States)에서 발행하는 학술지입니다. 식별자: eISSN 2590-0188. SCOPUS에 등재되어 있습니다. 지표: CiteScore 6.8, SJR 2.430, SNIP 0.96. tlooto에서 이 학술지의 논문 1,495편을 볼 수 있습니다.
CiteScore
6.80
Scopus 인용 지표
SJR
2.430
SCImago 저널 순위
SNIP
0.96
분야 보정 인용 영향력
Percentage rank
-
JIF 백분위 순위
저널 기본 정보
- ISSN
- -
- eISSN
- 2590-0188
- 약어
- -
- 출판사
- Elsevier
- 국가
- United States
Web of Science 카테고리
Web of Science 카테고리 정보가 없습니다.
Scopus ASJC 카테고리
2723 Immunology and Allergy2730 Oncology
이 학술지의 논문
최근 논문
- The effect of neoadjuvant radiotherapy on immune cell infiltrates in myxofibrosarcoma.
2026
- Redirecting engineered immune cells using G protein-coupled receptors in cancer therapy.
2026 · 인용 1회
- Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care.
2026 · 인용 2회
- The genome takes the wheel: CAR T with built-in circuits
2026
- Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy
2026 · 인용 1회
많이 인용된 논문
- Non-viral chimeric antigen receptor (CAR) T cells going viral
2023 · 인용 60회
- LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
2022 · 인용 36회
- MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial
2022 · 인용 32회
- ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing
2022 · 인용 31회
- 65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC
2024 · 인용 26회